Market Overview

What The GEN-003 News Means For Genocea

Share:
What The GEN-003 News Means For Genocea
Related GNCA
Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut
Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4

Genocea Biosciences Inc GNCA) announced late Monday that it is effecting a strategic shift to immuno-oncology. The company also said it would focus on the development of neoantigen cancer vaccines, including GEN-009, and that it would explore strategic alternatives for GEN-003.

Reacting to the announcements, the shares of the company are slumping 68.47 percent to $1.68.

Delving on Genocea's decision on GEN-003, Cowen noted that the company has been indicating for some time now that it would begin a phase III trial of GEN-003 if a partner or a source of funding is zeroed in.

GEN-003 is a protein subunit T cell-enabled therapeutic vaccine tested to reduce the duration and severity of clinical symptoms associated with moderate-to-severe genital herpes and to control transmission of the infection.

Analysts Phil Nadeau and Marc Frahm estimate that the phase III study would have cost the company about $150 million. Given the stock price of the company, the analysts think it could not have found a sufficiently attractive way to fund the phase III program.

Therefore, Cowen believes the company will no longer develop GEN-003 by itself and will advance the treatment candidate further only if a partner can be found.

See also: Attention Biotech Investors: September Ushers In Another Slew Of PDUFA Catalysts

"We continue to project that GEN-003 will be successfully developed, but now we assume that GNCA will receive a 17.5% royalty on sales, rather than capturing all economics," the firm said.

Given the changed expectations, the firm lowered its DCF-based price target from $40 to $10, but it maintains its Outperform rating on the shares of the company.

The firm noted that Genocea is stopping spending on GEN-003 and reducing workforce by 40 percent. As a result, the company expects annualized savings of $6.5 million in personal-related costs, the firm added.

Related Links: Credit Suisse Weighs In Ahead Of PTC Therapeutics' Thursday AdCom Panel For Translarna

Latest Ratings for GNCA

DateFirmActionFromTo
Mar 2018H.C. WainwrightInitiates Coverage OnBuy
Mar 2018Cantor FitzgeraldInitiates Coverage OnOverweight
Feb 2018BairdInitiates Coverage OnOutperform

View More Analyst Ratings for GNCA
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Price Target Reiteration Analyst Ratings Movers Best of Benzinga

 

Related Articles (GNCA)

View Comments and Join the Discussion!